Website
News25/Ratings12
Price$64.95-15.64 (-19.41%)
2026-01-202026-04-23
News · 26 weeks56+160%
2025-10-262026-04-19
Mix2690d
- Insider11(42%)
- SEC Filings6(23%)
- Other5(19%)
- Analyst2(8%)
- Earnings2(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by Rosebrough Walter M Jr4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
- PRCooperVision Partners with Canadian Olympic Speed Skater Valérie Maltais on Her Continued Pursuit of Excellence on the World StageRICHMOND HILL, ON, April 16, 2026 /CNW/ - CooperVision Canada is proud to announce a new partnership with Valérie Maltais, one of Canada's most decorated Olympic speed skaters, as she continues to pursue excellence both on the ice and in her academic studies. As she trains toward the next major international competitions, Maltais relies on MyDay Energys® contact lenses, which deliver premium optics shown to improve vision and comfort*1,2. Maltais' career is defined by speed, strategy, and precision. A five‑time Olympian and multi‑medalist, she competes in an environment where th
- PRCooperVision Launches MADE BETTER™ Promise Beginning with MyDay® Contact Lenses*¹New sustainability platform reflects company's commitment to responsible sourcing, moreefficient manufacturing, and offsetting a portion of plastic footprint*†1ROCHESTER, N.Y., April 9, 2026 /PRNewswire/ -- CooperVision announced today the launch of its MADE BETTER™ Promise—a new global sustainability platform focused on smarter, more sustainable choices.*†1 Built on years of CooperVision innovation in sustainability, MADE BETTER™ Promise is woven throughout the life of participating products, beginning with the MyDay® daily disposable family of contact lenses.*†1 COO), is one of the world's leading manufacturers of contact l
- PRTelix Strengthens Board with Additional Director AppointmentsMELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ:COO), a medical technology company, and also served as an independent director for Medidata
- SECThe Cooper Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
- INSIDERSEC Form 4 filed by Weiss Robert S4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
- INSIDERSEC Form 4 filed by Rivas Maria4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
- INSIDERSEC Form 4 filed by Jay Colleen4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
- INSIDERSEC Form 4 filed by Carbone Barbara4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
- INSIDERSEC Form 4 filed by Rosebrough Walter M Jr4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
- INSIDERSEC Form 4 filed by Madden Teresa S4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
- INSIDERSEC Form 4 filed by Lucchese Cynthia L4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
- INSIDERSEC Form 4 filed by Kurzius Lawrence Erik4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by The Cooper Companies Inc.SCHEDULE 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
- SECSEC Form 10-Q filed by The Cooper Companies Inc.10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)
- SECSEC Form 8-K filed by The Cooper Companies Inc.8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
- PRCooperCompanies Announces First Quarter 2026 ResultsSAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year's first quarter.First quarter 2026 GAAP diluted earnings per share (EPS) of $0.66, up $0.14 or 27% from last year's first quarter.First quarter 2026 Non-GAAP diluted EPS of $1.10, up $0.18 or 20% from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We're pleased to report a strong start to the fiscal year, highlighted by product launches,
- ANALYSTCooper downgraded by Rothschild & Co Redburn with a new price targetRothschild & Co Redburn downgraded Cooper from Buy to Neutral and set a new price target of $85.00
- SECSEC Form DEFA14A filed by The Cooper Companies Inc.DEFA14A - COOPER COMPANIES, INC. (0000711404) (Filer)
- SECSEC Form DEF 14A filed by The Cooper Companies Inc.DEF 14A - COOPER COMPANIES, INC. (0000711404) (Filer)
- INSIDERAmendment: SEC Form 4 filed by EVP, CFO & Treasurer Andrews Brian G4/A - COOPER COMPANIES, INC. (0000711404) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by President & CEO White Albert G Iii4/A - COOPER COMPANIES, INC. (0000711404) (Issuer)
- PRCooperVision Launches MiSight® 1 day in Japan; Becomes First Myopia Control Contact Lens in Leading Vision Care MarketCooperVision Strengthens Global Footprint with Expanded Access to Myopia Management in Asia-Pacific ROCHESTER, N.Y., Feb. 10, 2026 /PRNewswire/ -- CooperVision today announced immediate availability of its MiSight® 1 day* myopia control contact lens in Japan, where as many as 77% of elementary school children are estimated to be myopic, equating to millions who could benefit from myopia control treatments.1 The country represents approximately 12% of the global contact lens marketplace.2 MiSight® 1 day is the first soft contact lens authorized by Japan's Ministry of Health, La
- PRCooperCompanies Announces Release Date for First Quarter 2026SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful mo
- SECSEC Form 8-K filed by The Cooper Companies Inc.8-K - COOPER COMPANIES, INC. (0000711404) (Filer)